MMP Inhibitor Clinical Trials – The Past, Present, and Future

  • Barbara Fingleton


Various pharmacological inhibitors of matrix metalloproteinases (MMPs) have been tested in phase I, II, and III trials of multiple cancer types and no significant evidence of efficacy has emerged. This overwhelming failure has understandably led to questions regarding MMPs as suitable drug targets in the oncology setting. In this chapter, a synopsis of the various trials and their results is presented along with a discussion of dose-limiting toxicities and the contrasting successful preclinical testing of these agents. Thoughtful application of the lessons learnt from the MMP inhibitor clinical experience should improve the likelihood of successful proteinase inhibitors in the future.


Clin Oncol Advanced Pancreatic Cancer Malignant Pleural Effusion Matrix Metalloproteinase Inhibitor Sideroblastic Anemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Barbara Fingleton
    • 1
  1. 1.Dept. of Cancer BiologyVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations